Invokana Research Articles

SGLT2 Inhibitors Are Associated with Risks for Amputation and Diabetic Ketoacidosis

In randomized trials, patients with type 2 diabetes and elevated cardiovascular disease (CVD) risk who received canagliflozin (Invokana; a sodium

Canagliflozin-Associated Diabetic Ketoacidosis

The sodium–glucose cotransporter-2 (SGLT2) inhibitor canagliflozin (Invokana) is FDA-approved for use only in patients with type 2 diabetes. However,

More Information on the Diabetes Drug Canagliflozin

For diabetes treatment, the newest kid on the block is canagliflozin (Invokana), which lowers blood glucose levels by decreasing renal tubular reabsorption of glucose and increasing urinary glucose excretion. In this double-blind, industry-sponsored trial, researchers randomized 756 patients with longstanding type 2 diabetes — all of whom …